Items where authors include "Kavanaugh, A"

Article

Gladman, DD, Mease, PJ, Bird, P et al. (14 more authors) (2022) Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials, 23 (1). 743. ISSN 1745-6215

Coates, LC, Soriano, ER, Corp, N et al. (42 more authors) (2022) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nature Reviews Rheumatology, 18 (8). pp. 465-479. ISSN 1759-4790

Rahman, P, Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (10 more authors) (2021) Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Research and Therapy, 23 (1). 190. ISSN 1478-6354

Goel, N, FitzGerald, O, Gladman, DD et al. (6 more authors) (2019) GRAPPA 2018 Project Report. The Journal of Rheumatology Supplement, 95. pp. 54-57. ISSN 0380-0903

Jaworski, J, Matucci-Cerinic, M, Schulze-Koops, H et al. (6 more authors) (2019) Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Research and Therapy, 21 (1). 130. ISSN 1478-6354

Matucci-Cerinic, M, Allanore, Y, Kavanaugh, A et al. (8 more authors) (2018) Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. RMD Open, 4 (2). e000757. ISSN 2056-5933

Coates, LC orcid.org/0000-0002-4756-663X, Tillett, W, Shaddick, G et al. (3 more authors) (2018) Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight‐Control Clinical Trial and an Observational Cohort. Arthritis Care and Research, 70 (8). pp. 1198-1205. ISSN 2151-464X

Helliwell, PS and Kavanaugh, A (2018) Radiographic progression is less in psoriatic arthritis achieving a good response to treatment: data using newer composite indices of disease activity. Arthritis Care & Research, 70 (5). pp. 797-800. ISSN 2151-464X

Coates, LC orcid.org/0000-0002-4756-663X, FitzGerald, O, Merola, JF et al. (23 more authors) (2018) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. Arthritis & Rheumatology, 70 (3). pp. 345-355. ISSN 2326-5191

Smolen, JS, Aletaha, D, Barton, A et al. (8 more authors) (2018) Rheumatoid arthritis. Nature Reviews Disease Primers, 4. 18001.

Kavanaugh, A, van Vollenhoven, RF, Fleischmann, R et al. (7 more authors) (2018) Testing Treat-to-Target Outcomes With Initial Methotrexate Monotherapy Compared With Initial Tumor Necrosis Factor Inhibitor (Adalimumab) Plus Methotrexate in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 77 (2). pp. 289-292. ISSN 0003-4967

Smolen, JS, Schöls, M, Braun, J et al. (34 more authors) (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 77 (1). pp. 3-17. ISSN 0003-4967

Keystone, EC, Breedveld, FC, Heijde, DVD et al. (8 more authors) (2017) Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD Open, 3 (2). e000445. ISSN 2056-5933

Coates, LC orcid.org/0000-0002-4756-663X, Gossec, L, Smolen, JS et al. (5 more authors) (2017) New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced. Rheumatology, 56 (8). pp. 1251-1253. ISSN 1462-0324

Jadon, DR, Gladman, DD, Mease, PJ et al. (19 more authors) (2017) Proceedings of the GRAPPA 2016 Retreat. The Journal of Rheumatology, 44 (5). pp. 668-673. ISSN 0315-162X

Emery, P, Smolen, JS, Ganguli, A et al. (5 more authors) (2016) Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. Rheumatology, 55 (8). pp. 1458-1465. ISSN 1462-0324

Kavanaugh, A, Helliwell, P and Ritchlin, CT (2016) Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Rheumatology and Therapy, 3 (1). pp. 91-102. ISSN 2198-6576

De Lautour, H, Taylor, WJ, Adebajo, A et al. (36 more authors) (2016) Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care and Research, 68 (5). pp. 667-672. ISSN 2151-464X

Emery, P, Kavanaugh, A, Bao, Y et al. (2 more authors) (2015) Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? Annals of the Rheumatic Diseases, 74 (12). pp. 2165-2174. ISSN 0003-4967

Gossec, L, Smolen, JS, Gaujoux-Viala, C et al. (32 more authors) (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Annals of the Rheumatic Diseases, 71 (1). pp. 4-12. ISSN 0003-4967

Conference or Workshop Item

Kavanaugh, A, Liu, Y, Deodhar, A et al. (8 more authors) (2021) Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 DISCOVER Program. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Kavanaugh, A, Liu, Y, Deodhar, A et al. (8 more authors) (2021) Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 Discover Program. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Coates, LC, Soriano, E, Corp, N et al. (31 more authors) (2021) The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment Recommendations 2021. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Kavanaugh, A, Helliwell, P orcid.org/0000-0002-4155-9105, Sesin, C et al. (6 more authors) (2021) Low Disease Thresholds up to Three Years in Ixekizumab-Treated Patients with Psoriatic Arthritis in SPIRIT-P1 and SPIRIT-P2. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Merola, JF, Gottlieb, AB, Mease, P et al. (5 more authors) (2020) Psoriasis outcomes in a randomized trial of etanercept and methotrexate as monotherapy or in combination in patients with psoriatic arthritis. In: 2020 AAD VMX, 12-14 Jun 2020, Virtual.

Helliwell, P orcid.org/0000-0002-4155-9105, Mease, P, Kavanaugh, A et al. (9 more authors) (2020) What Influence Do Clinical Domains Other Than Arthritis Have on Composite Clinical Outcomes in Psoriatic Arthritis?: Comparison of Treatment Effects in the SEAM-PsA Trial. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Proceedings Paper

Helliwell, P, Gladman, DD, Chakravarty, SD et al. (5 more authors) (2018) Efficacy of Ustekinumab on Spondylitis-Associated Endpoints in TNF-Naïve Active Psoriatic Arthritis Patients with Physician-Reported Spondylitis. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .

Kavanaugh, A, Matucci-Cerinic, M, Schulze-Koops, H et al. (4 more authors) (2018) Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .